Results 181 to 190 of about 164,630 (292)
Targeted immunotherapies for Graves' thyroidal & orbital diseases. [PDF]
Lee ACH, Kahaly GJ.
europepmc +1 more source
To precisely modulate natural and synthetic regulatory parts, SUPER is introduced as a sophisticated and tunable controller of genetic devices without requiring sequence modification on the target. SUPER enhances dynamic range of RNA‐, chemical‐, temperature‐, and protein‐responsive biosensors up to 1011%, and converts biosensors to cover an expanded ...
Taeyang Heo +3 more
wiley +1 more source
Use of Robotic Surgery for the Management of Orbital Diseases: A Comprehensive Review. [PDF]
Nocini R +8 more
europepmc +1 more source
A new cerebrocortical organoid model using isogenic hiPSCs with familial Alzheimer's mutations recapitulates key AD features, including amyloid‐beta and phospho‐Tau aggregation, neuronal hyperexcitability, and synapse loss. Single‐cell RNA‐seq reveals aberrant pathways in excitatory and inhibitory neurons.
Sergio R. Labra +23 more
wiley +1 more source
Guidelines for standard operation of imaging modalities in orbital diseases (2024). [PDF]
Shao Y +3 more
europepmc +1 more source
An unusual cause of bilateral orbital swelling: Immunoglobulin G4–related orbital disease arising in a patient with ulcerative colitis [PDF]
Dawn Queen +3 more
openalex +1 more source
Targeting DESI2 as a Novel Therapeutic Strategy for JAK2‐Mutant Leukemias
Mass spectrometry‐based proteomics identify DESI2 as a novel component of the JAK2‐V617F complex, which associates with and stabilizes mutant JAK2 through deSUMOylation and deubiquitination, therefore promoting JAK2 mutant cell growth and MPN disease onset in vivo.
Husheng Mei +32 more
wiley +1 more source
Clinician's approach for spectrum of orbital diseases: An overview. [PDF]
Khan L.
europepmc +1 more source

